GEA Process Engineering A/S - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GEA Process Engineering A/S

Improve drug properties and production with spray drying

Spray drying is a technique preferred by a growing number of pharmaceutical companies to produce better drugs. This ultra-fast and gentle drying technology offers unique possibilities of producing powders with advanced properties - even under aseptic conditions.

Several companies are already benefitting from the technology as an ‘enabling technology’ - to improve the performance of poorly soluble APIs by producing an amorphous solid dispersion, to obtain controlled release or taste-masking, or to produce advanced powders with specific properties.

GEA Process Engineering - the company behind GEA Niro spray drying technology - is the leading provider of spray drying technology to the pharmaceutical industry, and is one of the few companies that offer a full range of spray drying units and services to companies working with the develop-ment of spray dried pharmaceuticals and pharmaceutical grade products. Our portfolio covers the complete development cycle - from the initial proof of concept tests where only a few milliliters of material are available to full-scale production of clinical trial materials and commercial products under cGMP conditions. For better results on any scale, look to GEA Process Engineering.

Website: www.niro.com
E-mail: gea-niro.pharma@gea.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
FindPharma Custom Search

Click here